JP5110314B2 - Sleep improving composition and sleep improving agent - Google Patents
Sleep improving composition and sleep improving agent Download PDFInfo
- Publication number
- JP5110314B2 JP5110314B2 JP2008513200A JP2008513200A JP5110314B2 JP 5110314 B2 JP5110314 B2 JP 5110314B2 JP 2008513200 A JP2008513200 A JP 2008513200A JP 2008513200 A JP2008513200 A JP 2008513200A JP 5110314 B2 JP5110314 B2 JP 5110314B2
- Authority
- JP
- Japan
- Prior art keywords
- sleep
- component
- composition
- improving
- per
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000007958 sleep Effects 0.000 title claims description 105
- 239000000203 mixture Substances 0.000 title claims description 63
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 52
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 36
- 235000021419 vinegar Nutrition 0.000 claims description 30
- 239000000052 vinegar Substances 0.000 claims description 30
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 19
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 17
- 230000006872 improvement Effects 0.000 claims description 17
- 235000007688 Lycopersicon esculentum Nutrition 0.000 claims description 15
- 240000003768 Solanum lycopersicum Species 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 10
- 239000003205 fragrance Substances 0.000 claims description 10
- 230000001624 sedative effect Effects 0.000 claims description 7
- 229940088594 vitamin Drugs 0.000 claims description 7
- 235000013343 vitamin Nutrition 0.000 claims description 7
- 239000011782 vitamin Substances 0.000 claims description 7
- 229930003231 vitamin Natural products 0.000 claims description 7
- 229920002770 condensed tannin Polymers 0.000 claims description 6
- 235000015110 jellies Nutrition 0.000 claims description 6
- 239000008274 jelly Substances 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- 244000004281 Eucalyptus maculata Species 0.000 claims description 4
- 235000010663 Lavandula angustifolia Nutrition 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 235000019634 flavors Nutrition 0.000 claims description 4
- 239000001102 lavandula vera Substances 0.000 claims description 4
- 235000018219 lavender Nutrition 0.000 claims description 4
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims description 3
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims description 3
- 235000011203 Origanum Nutrition 0.000 claims description 3
- 240000000783 Origanum majorana Species 0.000 claims description 3
- 235000009984 Pterocarpus indicus Nutrition 0.000 claims description 3
- 244000086363 Pterocarpus indicus Species 0.000 claims description 3
- 235000002911 Salvia sclarea Nutrition 0.000 claims description 3
- 244000182022 Salvia sclarea Species 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- 244000178870 Lavandula angustifolia Species 0.000 claims 1
- 244000042664 Matricaria chamomilla Species 0.000 claims 1
- 230000000694 effects Effects 0.000 description 21
- 230000008452 non REM sleep Effects 0.000 description 11
- 210000005259 peripheral blood Anatomy 0.000 description 10
- 239000011886 peripheral blood Substances 0.000 description 10
- 230000009471 action Effects 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 235000015203 fruit juice Nutrition 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 210000005037 parasympathetic nerve Anatomy 0.000 description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 description 4
- 235000013824 polyphenols Nutrition 0.000 description 4
- 235000013311 vegetables Nutrition 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 244000165082 Lavanda vera Species 0.000 description 3
- 235000011430 Malus pumila Nutrition 0.000 description 3
- 244000070406 Malus silvestris Species 0.000 description 3
- 235000015103 Malus silvestris Nutrition 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 3
- 244000078534 Vaccinium myrtillus Species 0.000 description 3
- 229960005069 calcium Drugs 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 2
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 240000002234 Allium sativum Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 240000003538 Chamaemelum nobile Species 0.000 description 2
- 241001672694 Citrus reticulata Species 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 235000016623 Fragaria vesca Nutrition 0.000 description 2
- 240000009088 Fragaria x ananassa Species 0.000 description 2
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229940124277 aminobutyric acid Drugs 0.000 description 2
- 229930014669 anthocyanidin Natural products 0.000 description 2
- 235000008758 anthocyanidins Nutrition 0.000 description 2
- 235000010208 anthocyanin Nutrition 0.000 description 2
- 229930002877 anthocyanin Natural products 0.000 description 2
- 239000004410 anthocyanin Substances 0.000 description 2
- 150000004636 anthocyanins Chemical class 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 235000021014 blueberries Nutrition 0.000 description 2
- 229960004494 calcium gluconate Drugs 0.000 description 2
- 239000004227 calcium gluconate Substances 0.000 description 2
- 235000013927 calcium gluconate Nutrition 0.000 description 2
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 2
- 235000005487 catechin Nutrition 0.000 description 2
- 210000004720 cerebrum Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229950001002 cianidanol Drugs 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- NWKFECICNXDNOQ-UHFFFAOYSA-N flavylium Chemical compound C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=[O+]1 NWKFECICNXDNOQ-UHFFFAOYSA-N 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 235000004611 garlic Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 2
- 235000008696 isoflavones Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 210000001002 parasympathetic nervous system Anatomy 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 230000003860 sleep quality Effects 0.000 description 2
- 239000010902 straw Substances 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 229940026510 theanine Drugs 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- 241000234282 Allium Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 240000007087 Apium graveolens Species 0.000 description 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 1
- 235000010591 Appio Nutrition 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 241001107116 Castanospermum australe Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 240000007154 Coffea arabica Species 0.000 description 1
- 235000016795 Cola Nutrition 0.000 description 1
- 244000228088 Cola acuminata Species 0.000 description 1
- 235000011824 Cola pachycarpa Nutrition 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 240000009226 Corylus americana Species 0.000 description 1
- 235000001543 Corylus americana Nutrition 0.000 description 1
- 235000007466 Corylus avellana Nutrition 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 244000108452 Litchi chinensis Species 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 235000014749 Mentha crispa Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 244000078639 Mentha spicata Species 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- 244000270834 Myristica fragrans Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 235000015742 Nephelium litchi Nutrition 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 244000062780 Petroselinum sativum Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 240000003889 Piper guineense Species 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 240000006909 Tilia x europaea Species 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000792914 Valeriana Species 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229940069765 bean extract Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000021279 black bean Nutrition 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 235000021329 brown rice Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000004424 eye movement Effects 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 235000019674 grape juice Nutrition 0.000 description 1
- 229940087603 grape seed extract Drugs 0.000 description 1
- 235000002532 grape seed extract Nutrition 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 235000021430 malt vinegar Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 238000012806 monitoring device Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000001702 nutmeg Substances 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- -1 pH adjusters Substances 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 235000011197 perejil Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940106587 pine bark extract Drugs 0.000 description 1
- 235000020741 pine bark extract Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000008667 sleep stage Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000015193 tomato juice Nutrition 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical group [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000001717 vitis vinifera seed extract Substances 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Description
本発明は、就寝前に摂取することにより、優れた睡眠改善効果、特に深いノンレム睡眠時間の増加効果が得られる睡眠改善用組成物に関するものである。 The present invention relates to a composition for improving sleep, which is obtained by taking it before going to bed, whereby an excellent sleep improving effect, in particular, an effect of increasing deep non-REM sleep time can be obtained.
睡眠は脳に休息を与えている状態であり、高等動物にとっては単なる活動停止の時間ではなく、高度の生理機能に支えられた適応行動である。睡眠がうまくとれないと大脳の情報処理能力に悪い影響が出る。例えば、睡眠が不足すると感じる不快な気分や意欲のなさは、身体の不調というよりも大脳そのものの機能低下に起因し、大脳が休息を要求していることを意味する。しかし、単に長時間睡眠をとってもあまりプラスには働かず、質の良い睡眠、即ち深い眠り(ノンレム睡眠)、特に深睡眠(ノンレム睡眠の睡眠段階3,4)をとることが質の高い生活に結びつく。 Sleep is a state in which the brain is rested, and for higher animals, it is not just a cessation of activity, but an adaptive behavior supported by high physiological functions. If you don't sleep well, your brain's information processing ability will be adversely affected. For example, an unpleasant mood or lack of motivation to feel that sleep is lacking means that the cerebrum is demanding resting due to a decline in the function of the cerebrum rather than a malfunction of the body. However, simply sleeping for a long time does not work very positively, and good quality sleep, that is, deep sleep (non-REM sleep), especially deep sleep (sleep stages 3 and 4 of non-REM sleep) is a high quality life. Tie.
睡眠に関わる技術として、CoQ10(特許文献1:特開2005−325086号公報参照)、テアニン(特許文献2:特開2005−289948号公報参照)、塩酸ジフェンヒドラミン(特許文献3:特開2005−179311号公報)、バレリアーナ属植物又はその抽出物(特許文献4:特開2003−183174号公報)、ラベンダー油等(特許文献5:特開2000−355545号公報)等が提案されている。しかしながら、不眠の原因は様々であり、さらに優れた睡眠改善効果、特に深いノンレム睡眠(深睡眠)時間の増加効果が得られるものが望まれていた。なお、本発明に関連する先行技術文献としては下記が挙げられる。 As technologies relating to sleep, CoQ10 (Patent Document 1: JP 2005-325086 A), theanine (Patent Document 2: JP 2005-289948 A), diphenhydramine hydrochloride (Patent Document 3: JP 2005-179411 A). No. 4), Valeriana plants or extracts thereof (Patent Document 4: JP 2003-183174 A), lavender oil, etc. (Patent Document 5: JP 2000-355545 A) and the like have been proposed. However, there are various causes of insomnia, and it has been desired to have an excellent sleep improvement effect, in particular, an effect of increasing deep non-REM sleep (deep sleep) time. In addition, the following is mentioned as a prior art document relevant to this invention.
本発明は上記事情に鑑みなされたもので、優れた睡眠改善効果、特に深いノンレム睡眠(深睡眠)時間の増加効果が得られる組成物を提供することを目的とする。 This invention is made | formed in view of the said situation, and it aims at providing the composition which can obtain the outstanding sleep improvement effect, especially the increase effect of deep non-REM sleep (deep sleep) time.
本発明者は、γ−アミノ酪酸(GABA)等の(A)副交感神経機能を高める作用を有する成分と、酢酸等の(B)末梢血流の増加を促す作用を有する成分とを組み合わせることにより、それぞれ単独で用いた場合には得られない優れた睡眠改善効果、特に深いノンレム睡眠時間の増加効果が得られ、熟眠感が得られることを知見した。本発明は、深睡眠の阻害要因のうち、末梢組織への血液供給を改善することが重要であるとの仮定からなされたもので、後述するデータが示すように、従来、睡眠に効果があることが知られていた(A)成分に加えて抹消血流の増加を促す(B)成分とを組み合わせることによって、(A)成分のみでは得られない睡眠改善効果が得られたものである。 The present inventor combined (A) a component having an action of enhancing parasympathetic nerve function such as γ-aminobutyric acid (GABA) and (B) a component having an action of promoting peripheral blood flow such as acetic acid. It was found that an excellent sleep improvement effect that cannot be obtained when used alone, in particular, an effect of increasing deep non-REM sleep time, and a deep sleep feeling can be obtained. The present invention is based on the assumption that it is important to improve the blood supply to peripheral tissues among the disturbing factors of deep sleep. As shown in the data described later, the present invention is conventionally effective for sleep. In addition to the component (A) that has been known, the combination of the component (B) that promotes the increase in peripheral blood flow provides a sleep improvement effect that cannot be obtained by the component (A) alone.
従って、下記発明を提供する。
[1].(A)γ−アミノ酪酸及び/又はグリシンと、(B)トマト酢とを含有する組成物であって、1回の睡眠あたりの(A)成分の摂取量が10〜3000mg、(B)成分中の酢酸としての摂取量が50〜3000mgとなるように含有する組成物であって、(A)成分/(B)成分中の酢酸の質量比が1/0.08〜1/100であることを特徴とする睡眠改善用組成物。
[2].(A)成分がγ−アミノ酪酸である[1]記載の睡眠改善用組成物。
[3].(A)γ−アミノ酪酸と、(B’)プロアントシアニジンとを含有する睡眠改善用組成物。
[4].(A)成分の1回の睡眠あたりの摂取量が2〜3000mg、(B’)成分の1回の睡眠あたりの摂取量が5〜1000mgである[3]記載の睡眠改善用組成物。
[5].(A)成分/(B’)成分の質量比が1/0.001〜1/500である[3]又は[4]記載の睡眠改善用組成物。
[6].さらに、鎮静作用を有する香料を含有する[1]〜[5]のいずれかに記載の睡眠改善用組成物。
[7].鎮静作用を有する香料が、ラベンダー、カモミール、クラリセージ、マージョラム、ユーカリ及びローズウッドから選ばれる香料である[6]記載の睡眠改善用組成物。
[8].さらに、ビタミンB6及び/又はカルシウムを含有する[1]〜[7]のいずれかに記載の睡眠改善用組成物。
[9].剤型がドリンク、濃縮液体、粉末、タブレット又はゼリーである[1]〜[8]のいずれかに記載の睡眠改善用組成物。
[10].就寝前に摂取される[1]〜[9]のいずれかに記載の睡眠改善用組成物。
[11].(A)γ−アミノ酪酸及び/又はグリシンと(B)トマト酢とを有効成分として含有する睡眠改善剤。
[12].1回の睡眠あたりの(A)成分の摂取量が10〜3000mg、(B)成分中の酢酸としての摂取量が50〜3000mgであって、(A)成分/(B)成分中の酢酸の質量比が1/0.08〜1/100である[11]記載の睡眠改善剤。
[13].(A)γ−アミノ酪酸と(B’)プロアントシアニジンとを有効成分として含有する睡眠改善剤。
[14].(A)成分の1回の睡眠あたりの摂取量が2〜3000mg、(B’)成分の1回の睡眠あたりの摂取量が5〜1000mgである[13]記載の睡眠改善剤。
[15].(A)成分/(B’)成分の質量比が1/0.001〜1/500である[13]又は[14]記載の睡眠改善剤。
Accordingly, the following invention is provided.
[1]. (A) A composition containing γ-aminobutyric acid and / or glycine , and (B) tomato vinegar , wherein the intake of (A) component per sleep is 10 to 3000 mg, (B) component It is a composition containing so that the intake as acetic acid in it may be 50-3000 mg, Comprising : The mass ratio of the acetic acid in (A) component / (B) component is 1 / 0.08-1 / 100 The composition for sleep improvement characterized by the above-mentioned.
[2]. (A) The composition for improving sleep according to [1], wherein the component is γ-aminobutyric acid.
[3]. A composition for improving sleep comprising (A) γ-aminobutyric acid and (B ′) proanthocyanidins.
[4]. The composition for improving sleep according to [ 3 ], wherein the intake amount per sleep of the component (A) is 2 to 3000 mg, and the intake amount of the component (B ′ ) per sleep is 5 to 1000 mg.
[5]. The composition for improving sleep according to [ 3 ] or [ 4 ], wherein the mass ratio of (A) component / (B ′ ) component is 1 / 0.001 to 1/500.
[6]. Furthermore, the composition for improving sleep according to any one of [1] to [ 5 ], further comprising a fragrance having a sedative effect.
[7]. The composition for improving sleep according to [6], wherein the fragrance having a sedative effect is a fragrance selected from lavender, chamomile, clary sage, marjoram, eucalyptus and rosewood.
[8]. Further comprises vitamin of B 6 and / or calcium [1] to sleep improvement composition according to any one of [7].
[9]. The composition for improving sleep according to any one of [1] to [ 8 ], wherein the dosage form is a drink, concentrated liquid, powder, tablet or jelly.
[10]. The composition for improving sleep according to any one of [1] to [ 9 ], which is taken before going to bed.
[11]. (A) A sleep improving agent containing γ-aminobutyric acid and / or glycine and (B) tomato vinegar as active ingredients.
[12]. The intake amount of component (A) per sleep is 10 to 3000 mg, the intake amount as acetic acid in component (B) is 50 to 3000 mg, and the amount of acetic acid in component (A) / component (B) The sleep improving agent according to [11], wherein the mass ratio is 1 / 0.08 to 1/100.
[13]. (A) A sleep improving agent containing γ-aminobutyric acid and (B ′) proanthocyanidins as active ingredients.
[14]. The sleep improving agent according to [13], wherein the intake amount per sleep of component (A) is 2 to 3000 mg, and the intake amount per sleep of component (B ′) is 5 to 1000 mg.
[15]. The sleep improving agent according to [13] or [14], wherein the mass ratio of component (A) / component (B ′) is 1 / 0.001 to 1/500.
本発明の睡眠改善用組成物によれば、優れた睡眠改善効果、特に深いノンレム睡眠時間を長くすることができ、起床時に満足な熟眠感を得ることができる。 According to the composition for improving sleep of the present invention, an excellent sleep improving effect, in particular, a deep non-REM sleep time can be lengthened, and a satisfactory sleep feeling can be obtained when waking up.
一般に睡眠中には「レム睡眠」と「ノンレム睡眠」が約90分を1単位として繰り返されており、眠りについてから約3時間の間に、深くぐっすりと眠っている状態である深いノンレム睡眠が集中する。睡眠障害の一つは、この深いノンレム睡眠がなくなり、あるいは短くなったりすることで、睡眠の質の低下につながっているといわれている。本発明の「睡眠改善」とは、特にこの深いノンレム睡眠の質及び時間を改善することで熟眠感を得、睡眠の質の向上に寄与しようというものである。 In general, “REM sleep” and “NREM sleep” are repeated for about 90 minutes as one unit during sleep, and deep non-REM sleep, which is a state of deep sleep, is about 3 hours after sleeping. concentrate. One of the sleep disorders is said to be due to the loss of sleep quality due to the disappearance or shortening of this deep non-REM sleep. The “sleep improvement” of the present invention is intended to contribute to the improvement of sleep quality by obtaining a deep sleep feeling by improving the quality and time of this deep non-REM sleep.
本発明の睡眠改善用組成物は、(A)副交感神経機能を高める作用を有する成分と、(B)末梢血流の増加を促す作用を有する成分とを、睡眠改善剤として含有する睡眠改善用組成物である。
(A)副交感神経機能を高める作用を有する好適な成分としては、γ−アミノ酪酸(GABA)、テアニン、トリプトファン及びグリシン等のアミノ酸が挙げられる。これらは1種単独で又は2種以上を適宜組み合わせて用いることができる。この中でもγ−アミノ酪酸が好ましい。γ−アミノ酪酸は、野菜や発芽玄米、お茶や発酵食品等一部の食品中に含まれている成分であり、脳内では神経伝達物質の一つとして神経興奮の抑制に関与している。The composition for improving sleep of the present invention comprises (A) a component having an action of enhancing parasympathetic nerve function and (B) a component having an action of promoting an increase in peripheral blood flow as a sleep improving agent. It is a composition.
(A) As a suitable component which has the effect | action which raises a parasympathetic nerve function, amino acids, such as (gamma) -aminobutyric acid (GABA), theanine, tryptophan, and glycine, are mentioned. These can be used individually by 1 type or in combination of 2 or more types. Among these, γ-aminobutyric acid is preferable. γ-aminobutyric acid is a component contained in some foods such as vegetables, germinated brown rice, tea and fermented foods, and is involved in the suppression of nerve excitement as one of the neurotransmitters in the brain.
γ−アミノ酪酸の調製方法は特に限定されず、野菜、果物、穀類から抽出する方法、乳タンパクから乳酸菌発酵により得る方法、特開2005−239686号公報記載の方法等が挙げられる。 The preparation method of (gamma) -aminobutyric acid is not specifically limited, The method of extracting from vegetables, fruits, cereals, the method of obtaining from lactic acid bacteria fermentation from milk protein, the method of Unexamined-Japanese-Patent No. 2005-239686, etc. are mentioned.
(A)副交感神経機能を高める作用を有する成分の摂取量は、1回の睡眠あたり2〜3000mg、好ましくは2.2〜2500mg、より好ましくは2.4〜2000mg、さらに好ましくは2.5〜1500mgである。特に好ましくは10〜1500mgである。これに応じて睡眠改善用組成物中の配合量を適宜選定する。例えば、1回の睡眠あたり50mL摂取する組成物であれば、組成物50mL中に2〜3000mg配合すればよい。 (A) The intake amount of the component having the effect of enhancing the parasympathetic nerve function is 2 to 3000 mg, preferably 2.2 to 2500 mg, more preferably 2.4 to 2000 mg, and further preferably 2.5 to 2 per sleep. 1500 mg. Particularly preferred is 10 to 1500 mg. According to this, the compounding quantity in the composition for sleep improvement is selected suitably. For example, if it is a composition which ingests 50mL per one sleep, what is necessary is just to mix | blend 2-3000 mg in 50mL of a composition.
(B)末梢血流の増加を促す作用を有する好適な成分としては、酢酸、ポリフェノールが挙げられ、1種単独で又は2種以上を適宜組み合わせて用いることができる。この中でも特に酢酸が好ましい。酢酸としては、酢酸を使用してもよいし食酢として配合してもよいが、食酢を配合することが好ましい。食酢としては、例えば、米酢、リンゴ酢、ブルーベリー酢等の果実酢、野菜酢、粕酢、麦芽酢、アルコール酢、蒸留酢、濃縮酢、黒酢、もろみ酢、トマト酢、合成酢が挙げられるが、米酢、果実酢、野菜酢、粕酢、アルコール酢、トマト酢が好適であり、特にトマト酢が好ましい。 (B) As a suitable component which has the effect | action which accelerates | stimulates the increase in peripheral blood flow, an acetic acid and a polyphenol are mentioned, It can use individually by 1 type or in combination of 2 or more types. Of these, acetic acid is particularly preferred. As acetic acid, acetic acid may be used or vinegar may be blended, but vinegar is preferably blended. Examples of vinegar include fruit vinegar such as rice vinegar, apple vinegar, blueberry vinegar, vegetable vinegar, straw vinegar, malt vinegar, alcohol vinegar, distilled vinegar, concentrated vinegar, black vinegar, moromi vinegar, tomato vinegar, and synthetic vinegar. However, rice vinegar, fruit vinegar, vegetable vinegar, straw vinegar, alcohol vinegar, and tomato vinegar are preferred, and tomato vinegar is particularly preferred.
なお、トマト酢は、上記(A)成分のγ−アミノ酪酸と、(B)成分の酢酸とを含むものである。トマト酢に含まれるγ−アミノ酪酸の量は、トマトの種類、栽培時期、栽培場所、熟度等により異なるが、加工用トマトの搾汁液100g中には50mg前後、品種名「桃太郎」トマトには、トマト100g中約50〜140mg含まれているといわれている。 Note that tomato vinegar contains γ-aminobutyric acid as component (A) and acetic acid as component (B). The amount of γ-aminobutyric acid contained in tomato vinegar varies depending on the type of tomato, cultivation time, cultivation place, maturity, etc., but in 100 g of tomato juice for processing, about 50 mg, the variety name “Momotaro” tomato Is said to be contained in about 50 to 140 mg in 100 g of tomato.
酢酸を用いる場合、その摂取量は1回の睡眠あたり50〜3000mgが好ましく、より好ましくは80〜2000mg、より好ましくは120〜1500mgである。これに応じて睡眠改善用組成物中の配合量を適宜選定する。例えば、1回の睡眠あたり50mL摂取する組成物であれば、組成物50mL中に50〜3000mg配合すればよい。 When acetic acid is used, the intake is preferably 50 to 3000 mg, more preferably 80 to 2000 mg, and more preferably 120 to 1500 mg per sleep. According to this, the compounding quantity in the composition for sleep improvement is selected suitably. For example, if it is a composition which ingests 50mL per sleep, what is necessary is just to mix | blend 50-3000 mg in 50mL of compositions.
ポリフェノールとしてはフラボノイドが好ましく、フラボノイドとしては、カテキン、プロアントシアニジン、アントシアニン、アントシアニジン、フラボノール、イソフラボン等が挙げられる。この中でも、カテキン、プロアントシアニジン、アントシアニン、アントシアニジンが好ましい。これらは植物抽出物や果汁として配合でき、また精製されたものを使用してもよい。これらの成分が含まれる植物抽出物や果汁としては、具体的には、緑茶エキス、ブドウ種子エキス、松樹皮エキス、大豆エキス、黒豆エキス、ブドウ果汁、グランベリー果汁、ブルーベリー果汁、ビルベリー果汁、リンゴ果汁が好適である。 The polyphenol is preferably a flavonoid, and examples of the flavonoid include catechin, proanthocyanidins, anthocyanins, anthocyanidins, flavonols, isoflavones and the like. Among these, catechin, proanthocyanidins, anthocyanins, and anthocyanidins are preferable. These can be blended as plant extracts or fruit juices, or purified ones may be used. Specific examples of plant extracts and fruit juices containing these ingredients include green tea extract, grape seed extract, pine bark extract, soybean extract, black bean extract, grape juice, granberry juice, blueberry juice, bilberry juice, apple Fruit juice is preferred.
ポリフェノールを用いる場合、その摂取量は1回の睡眠あたり5〜1000mgが好ましく、より好ましくは10〜800mg、さらに好ましくは20〜600mgである。これに応じて睡眠改善用組成物中の配合量を適宜選定する。例えば、1回の睡眠あたり50mL摂取する組成物であれば、組成物50mL中に5〜1000mg配合すればよい。 When using polyphenol, the intake is preferably 5 to 1000 mg per sleep, more preferably 10 to 800 mg, and still more preferably 20 to 600 mg. According to this, the compounding quantity in the composition for sleep improvement is selected suitably. For example, if it is a composition ingested 50 mL per sleep, 5-1000 mg may be mix | blended in 50 mL of compositions.
(B)成分が酢酸の場合、(A)成分/(B)成分の質量比は1/0.01〜1/1000が好ましく、より好ましくは1/0.08〜1/800であり、さらに好ましくは1/2〜1/500、特に好ましくは1/2〜1/300であり、最も好ましくは1/2〜1/100である。1/0.01を超えると、末梢組織に血液が十分供給できない場合があり、1/1000未満だと、副交感神経系の活動が優位になりにくい場合がある。 When component (B) is acetic acid, the mass ratio of component (A) / component (B) is preferably 1 / 0.01 to 1/1000, more preferably 1 / 0.08 to 1/800, It is preferably 1/2 to 1/500, particularly preferably 1/2 to 1/300, and most preferably 1/2 to 1/100. If the ratio exceeds 1 / 0.01, blood may not be sufficiently supplied to peripheral tissues. If the ratio is less than 1/1000, the activity of the parasympathetic nervous system may not be dominant.
(B)成分がポリフェノールの場合、(A)成分/(B)成分の好適な質量比は1/0.001〜1/500であり、好ましくは1/0.001〜1/100、より好ましくは1/0.08〜1/90、さらに好ましくは1/0.1〜1/80である。また、下限は1/40がさらに好ましく、特に好ましくは1/20、最も好ましくは1/12である。1/0.001を超えると、末梢組織に血液が十分供給できない場合があり、1/500未満だと、副交感神経系の活動が優位になりにくい場合がある。 When the component (B) is polyphenol, the preferred mass ratio of the component (A) / component (B) is 1 / 0.001 to 1/500, preferably 1 / 0.001 to 1/100, more preferably Is 1 / 0.08 to 1/90, more preferably 1 / 0.1 to 1/80. Further, the lower limit is more preferably 1/40, particularly preferably 1/20, and most preferably 1/12. If the ratio exceeds 1 / 0.001, blood may not be sufficiently supplied to peripheral tissues. If the ratio is less than 1/500, the activity of the parasympathetic nervous system may not be dominant.
本発明の睡眠改善用組成物には、さらに鎮静作用を有する香料を1種単独で又は2種以上を適宜組み合わせて配合すると、より熟眠感を得ることができる。鎮静作用を有する香料としては、ラベンダー、カモミール、クラリセージ、マージョラム、ユーカリ、ローズウッド等が挙げられ、この中でもラベンダー、ユーカリが好適である。これら香料の1回の睡眠あたりの摂取量は0.001〜3000mgが好ましく、香料の強さによって適宜調整することが好ましい。 In the composition for improving sleep of the present invention, when a perfume having a sedative action is added alone or in combination of two or more, a deep sleep feeling can be obtained. Examples of the fragrance having a sedative effect include lavender, chamomile, clary sage, marjoram, eucalyptus, rosewood, etc. Among them, lavender and eucalyptus are preferable. The amount of these perfumes consumed per sleep is preferably 0.001 to 3000 mg, and is suitably adjusted according to the strength of the perfumes.
さらに、冷え性を伴う睡眠改善効果のさらなる向上のために、ビタミンやミネラル、上記鎮静作用を有する香料以外のフレーバー等を1種単独で又は2種以上を適宜組み合わせて配合することが好ましい。ビタミンとしては、ビタミンB1、B2、B6、B12、C、A、D、E、K、ナイアシン、葉酸、パントテン酸、ビオチン、ユビキノン、これらの各誘導体が挙げられる。この中でも、B1、B2、B6、B12、Cが好ましい。ビタミンの1回の睡眠あたりの摂取量及び睡眠改善用組成物中の配合量は、栄養機能食品の栄養素の配合限度量に従うのが好ましい。Furthermore, in order to further improve the sleep-improving effect with cooling properties, it is preferable to blend vitamins, minerals, flavors other than the fragrance having the sedative action, etc., alone or in combination of two or more. Examples of vitamins include vitamins B 1 , B 2 , B 6 , B 12 , C, A, D, E, K, niacin, folic acid, pantothenic acid, biotin, ubiquinone, and their respective derivatives. Among these, B 1, B 2, B 6, B 12, C is preferable. It is preferable that the intake amount of vitamin per sleep and the blending amount in the composition for improving sleep conform to the blending limit amount of nutrients of the nutritional functional food.
ミネラルとしては、カルシウム、鉄、リン、マグネシウム、カリウム、セレン、亜鉛等が挙げられる。ミネラルの1回の睡眠あたりの摂取量及び睡眠改善用組成物中の配合量は、栄養機能食品の栄養素の配合限度量に従うのが好ましい。ビタミンやミネラルとしては、ビタミンB6及び/又はカルシウムを用いることが好ましい。Examples of minerals include calcium, iron, phosphorus, magnesium, potassium, selenium, and zinc. It is preferable that the intake amount of the mineral per sleep and the blending amount in the composition for improving sleep conform to the blending limit amount of nutrients of the nutritional functional food. As vitamins and minerals, vitamin B 6 and / or calcium is preferably used.
フレーバーとしては、レモン、オレンジ、グレープフルーツ、ライム、マンダリン、タンジェリン、アップル、バナナ、チェリー、グレープ、メロン、ピーチ、ストロベリー、ミルク、クリーム、バター、チーズ、ヨーグルト、コーヒー、紅茶、緑茶、ウーロン茶、ココア、コーラ、バニラ、ペパーミント、スペアミント、シナモン、ナツメグ、ペパー、ガーリック、ジンジャー、クローブ、アーモンド、ピーナッツ、ヘーゼルナッツ、マカダミアナッツ、トマト、オニオン、ガーリック、セロリー、パセリ、イチゴ、ライチ等が挙げられる。 Flavors include lemon, orange, grapefruit, lime, mandarin, tangerine, apple, banana, cherry, grape, melon, peach, strawberry, milk, cream, butter, cheese, yogurt, coffee, tea, green tea, oolong tea, cocoa, Examples include cola, vanilla, peppermint, spearmint, cinnamon, nutmeg, pepper, garlic, ginger, clove, almond, peanut, hazelnut, macadamia nut, tomato, onion, garlic, celery, parsley, strawberry and lychee.
フレーバーを用いる場合、その摂取量は1回の睡眠あたり0.1mg〜1000mgが好ましい。 When using a flavor, the intake is preferably 0.1 mg to 1000 mg per sleep.
本発明の睡眠改善用組成物には、さらに、栄養成分の補助として、(A)及び(B)成分以外の植物エキス、発酵微生物、カロテノイド、カルニチン、食物繊維、不飽和脂肪酸、キチン・キトサン、プロポリス、コラーゲン、イソフラボン、乳酸菌やビフィズス菌等の発酵微生物等を配合してもよい。その他、食品に用いられる原材料なら制限なく使用でき、例えば、上記以外の香料、ソルビトール、マルチトール、ステビア抽出物、アスパルテーム、アセスルファムカリウム、スクラロース、パラチノース等の甘味料、クエン酸、酒石酸、酪酸、核酸等の酸味料、上記[0016]に記載の果汁を除く他の果汁等の矯味剤、賦型剤、pH調整剤、乳化剤、増粘剤、防腐剤、溶解補助剤、着色料、(A)成分以外のアミノ酸等が挙げられる。 In the composition for improving sleep of the present invention, as an auxiliary to nutritional components, plant extracts other than components (A) and (B), fermenting microorganisms, carotenoids, carnitines, dietary fibers, unsaturated fatty acids, chitin / chitosan, You may mix | blend fermentation microorganisms, such as propolis, collagen, isoflavone, lactic acid bacteria, and bifidobacteria. Other ingredients that can be used in foods can be used without limitation. Acidulants such as those other than fruit juices described in [0016] above, corrigents such as other fruit juices, excipients, pH adjusters, emulsifiers, thickeners, preservatives, solubilizers, colorants, (A) Examples include amino acids other than the components.
本発明の睡眠改善用組成物の剤型は、ドリンク(飲料)、濃縮液体、粉末、タブレット又はゼリー等にすることができ、剤型の常法に基づいて、例えば上記成分、必要に応じて水(残部)を混合して得ることができる。 The dosage form of the sleep improving composition of the present invention can be a drink (beverage), a concentrated liquid, a powder, a tablet, a jelly, or the like. It can be obtained by mixing water (remainder).
本発明の睡眠改善用組成物は就寝前に摂取されることが好ましく、より好ましくは就寝直前〜就寝120分前に摂取するとよい。 The composition for improving sleep of the present invention is preferably taken before going to bed, more preferably taken immediately before going to bed and 120 minutes before going to bed.
以下、実施例、参考例及び比較例を示し、本発明を具体的に説明するが、本発明は下記の実施例に制限されるものではない。 EXAMPLES Hereinafter, although an Example, a reference example, and a comparative example are shown and this invention is demonstrated concretely, this invention is not restrict | limited to the following Example.
[実施例1〜5、参考例1〜5、比較例1〜5]
表1〜4に示すドリンク剤組成物(50mL;1本)を調製し、下記方法に基づいて、深睡眠量、末梢血流改善効果、熟眠感について評価した。結果を表中に併記する。
[ Examples 1-5, Reference Examples 1-5, Comparative Examples 1-5]
The drink composition (50 mL; 1) shown in Tables 1-4 was prepared, and the deep sleep amount, the peripheral blood flow improvement effect, and the feeling of deep sleep were evaluated based on the following method. The results are also shown in the table.
(1)深睡眠量の測定
30代女性3人にドリンク剤組成物1本を就寝30分前に飲用してもらい、就寝中の脳波、眼球運動、筋電図、呼吸運動、心電図、酸素飽和度、下肢の動き等を終夜記録する終夜睡眠ポリグラフ検査を行い、睡眠の深さを解析した。測定には終夜睡眠ポリグラフ(フクダ電子製)を用いた。深睡眠量は、脳が休んでいる状態であるノンレム睡眠のステージ3及び4段階の合計時間とした。結果を平均値で示す。
(2)末梢血流改善効果の測定(血管幅の測定)
冷え性の女性5人にドリンク剤組成物1本を摂取してもらい、ドリンク剤組成物摂取前後の手指の血管幅を末梢血管モニタリング装置(シスメックス社製アストリムSU)で測定した。結果は、ドリンク剤組成物摂取前の末梢血管幅を100%としたときのドリンク剤組成物摂取後の末梢血管幅の%をドリンク剤組成物摂取前後の末梢血管幅変化率(%)とし、平均値で示す(n=5)。
(3)熟眠感の評価
30代の睡眠に不満をもつ女性10人を5人ずつ2群に分けて、一方の群は先に試験ドリンク剤組成物1本を就寝30分前に1週間摂取し、1週間間隔をあけてプラセボ1本を就寝30分前に1週間摂取した。もう一方の群は、先にプラセボ1本を就寝30分前に1週間摂取し、1週間間隔をあけて試験ドリンク剤組成物1本を就寝30分前に1週間摂取した。各被験者について、飲料摂取中の症状を下記の評価基準において評価した。結果を10人の平均値で示す。
〈評価基準〉
0:試験ドリンク剤組成物とプラセボとで熟眠感が変わらなかった。
1:プラセボに比べ試験ドリンク剤組成物を摂取した場合が、熟眠感がやや得られた。
2:プラセボに比べ試験ドリンク剤組成物を摂取した場合が、熟眠感が得られた。(1) Measurement of deep sleep amount Three women in their 30s took one drink composition 30 minutes before bedtime, and EEG, eye movement, electromyogram, respiratory exercise, electrocardiogram, oxygen saturation during bedtime A polysomnographic examination was performed overnight to record the degree and movement of the lower limbs, and the depth of sleep was analyzed. An overnight polysomnograph (Fukuda Denshi) was used for the measurement. The amount of deep sleep was the total time of stages 3 and 4 of non-REM sleep, which is a state where the brain is resting. Results are shown as average values.
(2) Measurement of peripheral blood flow improvement effect (measurement of blood vessel width)
Five cold women were allowed to take one drink composition, and the blood vessel width of the fingers before and after taking the drink composition was measured with a peripheral blood vessel monitoring device (Astrim SU manufactured by Sysmex Corporation). As a result, the percentage of peripheral blood vessel width after ingesting the drink composition when the peripheral blood vessel width before ingesting the drink composition is taken as 100% is the rate of change in peripheral blood vessel width (%) before and after ingestion of the drink composition, The average value is shown (n = 5).
(3) Evaluation of a feeling of deep sleep 10 women who are dissatisfied with sleep in their 30s are divided into 2 groups of 5 each, and one group takes 1 test drink composition at 30 minutes before bedtime for 1 week. Then, one placebo was taken for one week 30 minutes before going to bed at an interval of one week. In the other group, one placebo was previously taken for 30 minutes before bedtime for 1 week, and one test drink composition was taken for 1 week 30 minutes before bedtime at an interval of 1 week. For each subject, symptoms during drinking were evaluated according to the following evaluation criteria. A result is shown by the average value of 10 persons.
<Evaluation criteria>
0: The feeling of deep sleep did not change between the test drink composition and the placebo.
1: Compared with placebo, a slightly sleepy feeling was obtained when the test drink composition was ingested.
2: A feeling of deep sleep was obtained when the test drink composition was ingested compared to placebo.
[実施例6〜9]
表5に示す組成の睡眠改善用ドリンクを、トマト酢、L−カルニチン、グルコン酸カルシウム、ニコチン酸アミド、ビタミン類、果汁、甘味料、保存料及び着色料を混合溶解し、その後、予め水に分散させたγ−アミノ酪酸を配合し、さらに香料、残りの水を加えて混合溶解してろ過し、滅菌充填して調製した。これらの睡眠改善用ドリンクはいずれも良好な睡眠改善効果を示した。
[Examples 6 to 9 ]
A drink for improving sleep having the composition shown in Table 5 is prepared by mixing and dissolving tomato vinegar, L-carnitine, calcium gluconate, nicotinamide, vitamins, fruit juice, sweetener, preservative and colorant, and then preliminarily added to water. Dispersed γ-aminobutyric acid was added, and a fragrance and the remaining water were added, mixed and dissolved, filtered, and sterilized to prepare. All of these drinks for improving sleep showed a good sleep improving effect.
[実施例10]
ゼリー剤
グラニュー糖50質量部、スクラロース0.02質量部、水飴50質量部、オレンジ果汁100質量部、水480質量部、カラギナン5質量部、ローカストビーンガム5質量部、クエン酸ナトリウム1.2質量部、香料1.5質量部、γ−アミノ酪酸5質量部、トマト酢12質量部(酢酸換算0.6質量部)、グルコン酸カルシウム1質量部、ビタミンB20.02質量部、ビタミンB60.02質量部、ビタミンC0.2質量部、乳化剤0.8質量部を加熱溶解した。次いで、型に流し込み、一夜静置することにより、ゼリーを得た。このゼリー剤は良好な睡眠改善効果を示した。
[Example 10 ]
Jelly agent 50 parts by weight of granulated sugar, 0.02 part by weight of sucralose, 50 parts by weight of starch syrup, 100 parts by weight of orange juice, 480 parts by weight of water, 5 parts by weight of carrageenan, 5 parts by weight of locust bean gum, 1.2 parts by weight of sodium citrate Parts, fragrance 1.5 parts by weight, γ-aminobutyric acid 5 parts by weight, tomato vinegar 12 parts by weight (acetic acid equivalent 0.6 parts by weight), calcium gluconate 1 part by weight, vitamin B 2 0.02 parts by weight, vitamin B 6 0.02 parts by mass, 0.2 parts by mass of vitamin C, and 0.8 parts by mass of an emulsifier were dissolved by heating. Then, it was poured into a mold and left overnight to obtain a jelly. This jelly agent showed a good sleep improving effect.
Claims (15)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008513200A JP5110314B2 (en) | 2006-04-28 | 2007-04-24 | Sleep improving composition and sleep improving agent |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006125178 | 2006-04-28 | ||
JP2006125178 | 2006-04-28 | ||
PCT/JP2007/058784 WO2007125883A1 (en) | 2006-04-28 | 2007-04-24 | Composition for improvement in sleep quality |
JP2008513200A JP5110314B2 (en) | 2006-04-28 | 2007-04-24 | Sleep improving composition and sleep improving agent |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2007125883A1 JPWO2007125883A1 (en) | 2009-09-10 |
JP5110314B2 true JP5110314B2 (en) | 2012-12-26 |
Family
ID=38655409
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008513200A Active JP5110314B2 (en) | 2006-04-28 | 2007-04-24 | Sleep improving composition and sleep improving agent |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP5110314B2 (en) |
WO (1) | WO2007125883A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4773502B2 (en) * | 2008-11-27 | 2011-09-14 | 株式会社 伊藤園 | Container-packed vinegar beverages for warming and chilling improvers |
JP2011051970A (en) * | 2009-08-07 | 2011-03-17 | Kose Corp | Perfume composition for use in sleep improvement, and cosmetic containing the same, and method for improving sleep |
JP5585075B2 (en) * | 2009-12-24 | 2014-09-10 | ライオン株式会社 | Growth hormone secretagogue |
JP2014172892A (en) * | 2013-03-12 | 2014-09-22 | Fujifilm Corp | Sleep improvement agent, non-rem sleep period increasing agent and sedative agent |
JP6665099B2 (en) * | 2014-08-29 | 2020-03-13 | わかもと製薬株式会社 | Lactic acid bacteria-containing composition |
JP7037161B2 (en) * | 2016-07-07 | 2022-03-16 | 株式会社東洋新薬 | Oral composition |
EP3868215A4 (en) * | 2018-10-16 | 2022-07-27 | Nippon Chemiphar Co., Ltd. | Agent for improving quality of sleep |
JP6931012B2 (en) * | 2019-01-21 | 2021-09-01 | 台灣中油股▲ふん▼有限公司 | Cooking method with high production of γ-aminobutyric acid |
JP6863637B1 (en) * | 2020-07-01 | 2021-04-21 | 株式会社東洋新薬 | Composition for improving sleep |
WO2024142285A1 (en) * | 2022-12-27 | 2024-07-04 | フジッコ株式会社 | Sleep improving agent |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001316256A (en) * | 2000-04-28 | 2001-11-13 | Taiyo Kagaku Co Ltd | Composition for ameliorating blood flow |
JP2003009820A (en) * | 2001-07-05 | 2003-01-14 | Hosoda Shoten:Kk | Auxiliary food ingredient and food added with the auxiliary food ingredient |
JP2003183174A (en) * | 2001-12-19 | 2003-07-03 | Fancl Corp | Composition for insomnia |
JP2003533547A (en) * | 2000-05-26 | 2003-11-11 | ハドソン,スーザン,ピー | Plant-derived tryptophan source and use thereof |
JP2005000040A (en) * | 2003-06-10 | 2005-01-06 | Nanto Shuhan Kk | Moromi-su processed product and method for producing the same |
JP2005082495A (en) * | 2003-09-04 | 2005-03-31 | Pharma Foods International Co Ltd | Cerebral cell-protecting composition |
WO2005067738A1 (en) * | 2004-01-14 | 2005-07-28 | Ajinomoto Co., Inc. | Glycine-containing food and use thereof |
JP2005198645A (en) * | 2003-05-22 | 2005-07-28 | Lion Corp | Fermented liquid of tomato, hypotensive agent, method for producing the same, and eating and drinking composition |
JP2005239694A (en) * | 2004-02-27 | 2005-09-08 | Taiyo Kagaku Co Ltd | Anti-stress composition |
JP2005245419A (en) * | 2004-03-04 | 2005-09-15 | Hideyo Sasaya | Healthy food |
JP2005289948A (en) * | 2004-04-06 | 2005-10-20 | Taiyo Kagaku Co Ltd | Sleep improvement composition |
WO2005097101A1 (en) * | 2004-04-06 | 2005-10-20 | Taiyokagaku Co., Ltd. | Sleep-improving composition |
JP2006061089A (en) * | 2004-08-27 | 2006-03-09 | Pharma Foods International Co Ltd | Functional mayonnaise-like seasoning or dressing |
JP2006158330A (en) * | 2004-12-09 | 2006-06-22 | Kazuhiro Kotani | Health food containing black soybean skin and method for producing the same |
JP2007238520A (en) * | 2006-03-09 | 2007-09-20 | Ueda Holdings:Kk | Health food and supplement for sleep-inducement |
-
2007
- 2007-04-24 JP JP2008513200A patent/JP5110314B2/en active Active
- 2007-04-24 WO PCT/JP2007/058784 patent/WO2007125883A1/en active Application Filing
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001316256A (en) * | 2000-04-28 | 2001-11-13 | Taiyo Kagaku Co Ltd | Composition for ameliorating blood flow |
JP2003533547A (en) * | 2000-05-26 | 2003-11-11 | ハドソン,スーザン,ピー | Plant-derived tryptophan source and use thereof |
JP2003009820A (en) * | 2001-07-05 | 2003-01-14 | Hosoda Shoten:Kk | Auxiliary food ingredient and food added with the auxiliary food ingredient |
JP2003183174A (en) * | 2001-12-19 | 2003-07-03 | Fancl Corp | Composition for insomnia |
JP2005198645A (en) * | 2003-05-22 | 2005-07-28 | Lion Corp | Fermented liquid of tomato, hypotensive agent, method for producing the same, and eating and drinking composition |
JP2005000040A (en) * | 2003-06-10 | 2005-01-06 | Nanto Shuhan Kk | Moromi-su processed product and method for producing the same |
JP2005082495A (en) * | 2003-09-04 | 2005-03-31 | Pharma Foods International Co Ltd | Cerebral cell-protecting composition |
WO2005067738A1 (en) * | 2004-01-14 | 2005-07-28 | Ajinomoto Co., Inc. | Glycine-containing food and use thereof |
JP2005239694A (en) * | 2004-02-27 | 2005-09-08 | Taiyo Kagaku Co Ltd | Anti-stress composition |
JP2005245419A (en) * | 2004-03-04 | 2005-09-15 | Hideyo Sasaya | Healthy food |
JP2005289948A (en) * | 2004-04-06 | 2005-10-20 | Taiyo Kagaku Co Ltd | Sleep improvement composition |
WO2005097101A1 (en) * | 2004-04-06 | 2005-10-20 | Taiyokagaku Co., Ltd. | Sleep-improving composition |
JP2006061089A (en) * | 2004-08-27 | 2006-03-09 | Pharma Foods International Co Ltd | Functional mayonnaise-like seasoning or dressing |
JP2006158330A (en) * | 2004-12-09 | 2006-06-22 | Kazuhiro Kotani | Health food containing black soybean skin and method for producing the same |
JP2007238520A (en) * | 2006-03-09 | 2007-09-20 | Ueda Holdings:Kk | Health food and supplement for sleep-inducement |
Also Published As
Publication number | Publication date |
---|---|
WO2007125883A1 (en) | 2007-11-08 |
JPWO2007125883A1 (en) | 2009-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5110314B2 (en) | Sleep improving composition and sleep improving agent | |
JP3907964B2 (en) | Mental fatigue reducing composition, concentration maintenance enhancing composition and mental vitality maintenance enhancing composition | |
JP2006526398A (en) | Weight control beverage | |
MXPA06012501A (en) | Nutritional composition which promotes weight loss, burns calories, increases thermogenesis, supports energy metabolism and/or suppresses appetite. | |
JP2008061511A (en) | Flavor-improving agent, flavor-improving method using the flavor-improving agent, and food and drink | |
KR20090037403A (en) | Senescence inhibitor | |
JP2008063321A (en) | Muscle ageing inhibitor | |
JP6208604B2 (en) | Body fat reducing agent | |
CN101484157A (en) | Agent for improving muscle power | |
AU2002305703A1 (en) | Carbohydrate modifying agent and drinks containing the modifying agent | |
EP1404351A1 (en) | Carbohydrate modifying agent and drinks containing the modifying agent | |
JP2008063318A (en) | Aging inhibitor | |
JP2008031148A (en) | Agent for improving muscle power | |
JP2004262927A (en) | Serum cholesterol-reducing agent, food or drink, and method for producing the same | |
JP6756395B2 (en) | Beverage | |
JP2006028051A (en) | Ameliorant for exhausted feeling at time of rising, composition for ameliorating exhausted feeling at time of rising, and food and beverage for ameliorating exhausted feeling at time of rising, containing them | |
JP2010111608A (en) | Muscle damage inhibitor | |
JP2005139135A (en) | Prophylactic and ameliorating agent of menopausal disorder | |
JP2011006355A (en) | Composition and food and drink for improving bone density | |
JP4141271B2 (en) | Citrus extract composition | |
JP2008031080A (en) | Lipid utilization-promoting composition | |
JP2004215578A (en) | Composition for health food product and health food product or health beverage product | |
JP2009023948A (en) | Dopamine-inhibiting agent | |
KR20240092706A (en) | Composition for promoting and improving sleep for solid food and jelly, and manufacturing method thereof | |
JP2009155291A (en) | Hair-growing agent for preventing stress-related depilation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100223 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120516 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120713 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120912 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120925 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151019 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5110314 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |